Search the Newsreel

Spyre Therapeutics stock hits 52-week high at 105.11 USD By Investing.com

Spyre Therapeutics (SYRE) stock has reached a new 52-week high of $105.11, marking a significant 517.49% increase over the past year and achieving a market capitalization of $9.23 billion. This surge is driven by strong investor confidence and positive phase 2 trial results for …

Spyre Therapeutics (SYRE) Earnings Date and Reports 2026 $SYRE

SYRE (NASDAQ: SYRE) insider schedules 30,000-share stock sale notice

SYRE insider Scott Burrows has filed a Form 144 notice to sell 30,000 shares of common stock through Morgan Stanley Smith Barney LLC on August 3, 2026, related to the exercise of stock options. The aggregate value of this planned sale is $2,949,900.00. The …

Spyre Therapeutics, Inc. $SYRE is Perceptive Advisors LLC's 7th Largest Position

178,389 Shares in Spyre Therapeutics, Inc. $SYRE Acquired by First Trust Advisors LP

Spyre Therapeutics, Inc. $SYRE Shares Sold by Janus Henderson Group PLC

Spyre Therapeutics Inc (SYRE) Institutional Confidence

This article analyzes the institutional confidence in Spyre Therapeutics Inc (SYRE), highlighting its strong score of 10.00 within the Biotechnology & Medical Research industry. Institutional shareholding has increased by 19.72% quarter-over-quarter, with Fidelity Management & Research Company LLC and BlackRock Institutional Trust Company, N.A. …

Stempoint Capital LP Buys 135,229 Shares of Spyre Therapeutics, Inc. $SYRE

SYRE|Spyre Therapeutics Inc|Price:99.940|Chg%:-0.100

This article provides a comprehensive stock analysis of Spyre Therapeutics Inc. (SYRE), highlighting its relatively weak fundamentals but high growth potential, fair valuation, and strong institutional ownership. It details the company's clinical-stage biotechnology focus on inflammatory bowel disease (IBD) and other immune-mediated diseases, outlining …

Wolfe Research downgrades Spyre stock rating on valuation concerns By Investing.com

Wolfe Research downgraded Spyre Therapeutics (NASDAQ:SYRE) to Peerperform from Outperform due to valuation concerns, setting a fair value range of $96 to $113 per share. The firm noted that the stock is currently trading at $100, near its 52-week high, and expressed a lack …

Spyre Therapeutics Inc (SYRE) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Spyre Therapeutics Inc (SYRE), detailing its current stock price momentum, support and resistance levels, and insights from various technical indicators and moving averages. While the overall signal is Neutral according to technical analysis, the moving averages show …

Spyre Therapeutics Inc (SYRE) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Spyre Therapeutics Inc's (SYRE) dividend and stock split history. It indicates that SYRE has distributed no dividends over the past five years. The company did experience multiple "Merger 25→1" stock splits on September 7, 2023.

Spyre Therapeutics Inc (SYRE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey attempts to provide a revenue breakdown for Spyre Therapeutics Inc (SYRE), including business segments, regional revenue, and profit contribution. However, the article states that relevant data for these categories have not yet been disclosed by the company. It therefore presents …

Spyre Therapeutics Inc (SYRE) Valuation: PE, PB & Fair Value Analysis

The article provides a valuation analysis of Spyre Therapeutics Inc (SYRE), detailing its current valuation score, P/E ratio, and ranking within the Biotechnology & Medical Research industry. It notes that several key valuation metrics like P/B, P/S, and P/CF have not yet been disclosed …

ETFs Investing in Spyre Therapeutics, Inc Stocks

This article lists various Exchange Traded Funds (ETFs) that hold stocks of Spyre Therapeutics, Inc. (SYRE). It provides a detailed table including each fund's market value, weight of SYRE in the fund, issuer, management style, focus, expense ratio, assets under management (AUM), price, change …

Spyre Therapeutics Inc. (SYRE) Q1 2026 Earnings: Pre-Revenue Biotech Reports Wider-than-Expected Loss, Stock Gains 6.5% - Earnings Revision Report

SYRE Stock Draws Analyst Upgrades As Volatility Spikes

Spyre Therapeutics Inc.'s stock (SYRE) is experiencing increased volatility and analyst upgrades following positive clinical trial data for its inflammatory bowel disease platform. Mizuho and Deutsche Bank have raised their price targets significantly, reflecting optimism about the company's lead drug SPY120 and its multi-asset …

Spyre Therapeutics stock hits 52-week high at 102.46 USD

Spyre Therapeutics (SYRE) stock reached a new 52-week high of $102.46, marking a significant surge from its 52-week low. This performance is attributed to positive phase 2 trial results for SPY002 targeting ulcerative colitis and completed enrollment for SPY072 in rheumatic diseases, alongside optimistic …